Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-08-07
2003-09-30
Benzion, Gary (Department: 1634)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024300, C435S006120, C435S091200
Reexamination Certificate
active
06627745
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel genomic DNA sequence (MEFV) encoding a protein (pyrin) associated with familial Mediterranean fever (FMF). More specifically, the invention relates to the isolation and characterization of MEFV, and the correlation of mutations in MEFV with FMF disease.
2. Background of the Invention
Familial Mediterranean Fever (FMF) is a recessively inherited disorder characterized by dramatic episodes of fever, serosal inflammation and abdominal pain. This inflammatory disorder is episodic, with self-limited bouts of fever accompanied by unexplained arthritis, sterile peritonitis, pleurisy and/or skin rash. Patients often develop progressive systemic amyloidosis from the deposition of the acute phase reactant serum amyloid A (SAA). In some patients, progressive systemic amyloidosis can lead to kidney failure and death. The factors which incite an episode are unclear.
FMF is observed primarily in individuals of non-Ashkenazi Jewish, Armenian, Arab and Turkish background. Although rare in the United States, incidence of FMF in Middle Eastern populations can be as high as 1:7 in Armenian populations and 1:5 in non-Ashkenazi Jewish populations.
FMF attacks are characterized by a massive influx of polymorphonuclear leukocytes (PMNs) into the affected anatomic compartment. At the biochemical level, patients have been reported to have abnormal levels of C5a inhibitor (Matzner and Brzezinski, “C5a-inhibitor deficiency in peritoneal fluids from patients with familial Mediterranean fever,”
N. Engl. J. Med.,
311:287-290 (1984)), neutrophil-stimulatory dihydroxy fatty acids (Aisen et al, “Circulating hydroxy fatty acids in familial Mediterranean fever,”
Proc. Natl. Acad. Sci. USA,
2:1232-1236 (1985)), and dopamine &bgr;-hydroxylase (Barakat et al, “Plasma dopamine beta-hyroxylase: rapid diagnostic test for recurrent hereditary polyserositis,”
Lancet,
2:1280-1283 (1988)). Although linkage studies have placed the gene causing FMF (designated MEFV) on chromosome 16p (Pras et al., “Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16,”
N. Engl. J. Med.,
326:1509-1513 (1992); Shohat et al., “The gene for familial Mediterranean fever in both Armenians and non-Ashkenazi Jews is linked to the &agr;-globin complex on 16p: evidence for locus homogeneity,”
Am. J. Hum. Genet.,
51:1349-1354 (1992); Pras et al, “The gene causing familial Mediterranean fever maps to the short arm of chromosome 16 in Druze and Moslem Arab families,”
Hum. Genet.,
94:576-577(1994); French FMF Consortium, “Localization of the familial Mediterranean fever gene (FMF) to a 250 kb-interval in non-Ashkenazi Jewish founder haplotypes,”
Am. J. Hum. Genet.,
59:603-612(1996)), the genetic basis of FMF has not previously been identified.
Current treatment regimens for FMF include daily oral administration of colchicine. Although colchicine has been shown to cause near complete remission in about 75% of FMF patients and prevent amyloidosis, colchicine is not effective in all patients. Therefore, there is a need for new treatments for colchicine-resistant patients.
Additionally, there is a need for an accurate diagnostic test for FMF. Patients having FMF in countries where the disease is less prevalent often experience years of attacks and several exploratory surgeries before the correct diagnosis is made.
SUMMARY OF THE INVENTION
The invention provides a novel genomic nucleic acid sequence (MEFV) (SEQ ID NO:1), shown in
FIG. 1
, encoding the protein pyrin which is associated with familial Mediterranean fever (FMF). The corresponding cDNA sequence (v75-1) (SEQ ID NO:2) and encoded amino acid sequence (SEQ ID NO:3) are shown in FIG.
2
. The invention is also directed towards fragments of the DNA sequence that are useful, for example, as hybridization probes for diagnostic assays or oligonucleotides for PCR priming. Additionally, the invention is directed towards the corresponding sequence for the RNA transcript and fragments thereof.
Another aspect of the invention provides the amino acid sequence for a protein associated with FMF. This protein is called pyrin, to connote its relationship to fever. The invention is directed towards both the full length amino acid sequence, fusion proteins containing the amino acid sequence and fragments thereof. These proteins are useful, for example, as antigens to produce specific anti-pyrin antibodies to be used as agents in diagnostic assays. Alternatively, the protein may be used in therapeutic compositions.
Mutations in pyrin result in FMF. Therefore, the invention is also directed towards mutants of the nucleic acid and amino acid sequences associated with FMF. In particular, the invention discloses three missense mutations, clustered in within about 40 to 50 amino acids, in the highly conserved rfp (B30.2) domain (SEQ ID NO:5) at the C-terminal of the protein. These mutants include M680I, M694V, K695R and V726A, each of which is associated with FMF.
Additionally, the invention includes methods for diagnosing a patient at risk for having FMF using the nucleic acid and/or amino acid sequences of the invention. Such methods include, for example, hybridization techniques using nucleic acid sequences, PCR-amplification of MEFV, and immunoassays using anti-pyrin antibodies to identify mutations is MEFV or pyrin which are indicative of FMF.
REFERENCES:
patent: 5474796 (1995-12-01), Brennan
patent: 5840686 (1998-11-01), Chader et al.
patent: Wo-95/17205 (1995-06-01), None
Telatar et al. “Molecular Genetic Testing for Familial Mediterranean Fever” Molecular Genetics and Metabolism. Vol 71, pp. 256-260, Oct. 2000.*
Pras et al. “Familial Mediterranean Fever: From the Clinical Syndrome to the cloning of the pyrin gene”. Scand J. Rheumatol. VOl 27, pp. 92-97, 1998.*
New England Biolabs Catalog 96/97, p. 111.*
Boehringer Mannheim 1997 Bhochemical Catalog, p. 95.*
Ahren, “Biochemical Reagent Kits Offer Scientists good retun on investment” The Scientist, VOl 9, No. 1'5, p. 20, Jul. 24, 1995.*
Bernot et al. “Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF)”Human Molecular Genetics7(8):1317-25, Aug. 1998.
Bernot et al. “A transcriptional map of the FMF region”Genomics50:147-160, 1998.
French FMF Consortium: “A candidate gene for familial Mediterranean fever”Nature Genetics17(1):25-31, Sep. 1, 1997.
The International FMF Consortium: “Ancient Missense Mutations in a New Member of The RoRet Gene Family are Likely to Cause Familial Mediterranean Fever”Cell90(4):797-807, Aug. 22, 1997.
Sood et al. “Construction of a 1-MB Restriction-Mapped Cosmid Contig Containing the Candidate Region for the Familial Mediterranean Fever Locus (MEFV)on Chromosome 16P13.3” 42(1):83-95, May 15, 1997.
McKusick et al. “Mediterranean fever, familial; MEFV” NCBI—Online XP-002090817, 1999.
Aksentijevichh Ivona
Blake Trevor
Centola Michael
Collins Francis S.
Deng Zuoming
Benzion Gary
Goldberg Jeanine
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
Pyrin gene and mutants thereof, which cause familial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrin gene and mutants thereof, which cause familial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrin gene and mutants thereof, which cause familial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3100531